{"rows":[{"id":5791,"title":"A Molecule-Resolved Bibliometric Analysis of PubMed-Indexed Psychedelic Research (2015-2025): Volume, Temporal Trends, and Publication Types","authors":"M. Pastuszak, K. Jakuszkowiak-Wojten, M. Gałuszko-Węgielnik, A. W. Kwaśny, A. Mechlińska, D. Świeczkowski, W. J. Cubała","journal":"European Psychiatry","publication_date":"2026-06-01","publication_year":2026,"doi":"10.1192/j.eurpsy.2026.11510","pubmed_id":null,"openalex_id":"https://openalex.org/W7171946191","source_url":"https://doi.org/10.1192/j.eurpsy.2026.11510","substance_tags":"psilocybin,psilocin","topic_tags":"Mechanism of Action,Biomarkers,Meta-Analysis,Systematic Review,Review Article,Case Report,Toxicity","study_type":"Meta-Analysis","source_name":"OpenAlex","publication_status":"published","date_added":"2026-08-09 08:25:07","last_checked":"2026-08-09 08:25:07","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2026.11510","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2026.11510","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2026.11510","source_url":"https://doi.org/10.1192/j.eurpsy.2026.11510","doi":"10.1192/j.eurpsy.2026.11510","pmid":"","publication_date":"2026-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5638,"title":"Biophotons, hallucinogens, and fluorescence","authors":"F. Grass","journal":"European Psychiatry","publication_date":"2011-02-28","publication_year":2011,"doi":"10.1016/s0924-9338(11)72907-8","pubmed_id":null,"openalex_id":"https://openalex.org/W2067927319","source_url":"https://doi.org/10.1016/s0924-9338(11)72907-8","substance_tags":"psilocin","topic_tags":"Pharmacology","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:10","last_checked":"2026-07-04 06:52:10","bibtex":null,"source_record_id":"DOI:10.1016/s0924-9338(11)72907-8","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/s0924-9338(11)72907-8","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/s0924-9338(11)72907-8","source_url":"https://doi.org/10.1016/s0924-9338(11)72907-8","doi":"10.1016/s0924-9338(11)72907-8","pmid":"","publication_date":"2011-02-28","importer_version":"2.1.3","text_redistributed":false}},{"id":5303,"title":"EPA-0137 - EEG power spectra and connectivity changes in animal serotonergic and glutamatergic models of psychosis - implications for treatment","authors":"Tomáš Páleníček, Filip Tylš, M. Fujáková, Anna Kubešová, Pavlína Nováková, L. Kadeřábek, Martin Brunovský, Jiřı́ Horáček","journal":"European Psychiatry","publication_date":"2013-12-31","publication_year":2013,"doi":"10.1016/s0924-9338(14)77609-6","pubmed_id":null,"openalex_id":"https://openalex.org/W1978519803","source_url":"https://doi.org/10.1016/s0924-9338(14)77609-6","substance_tags":"psilocybin,psilocin","topic_tags":"Brain Imaging,Receptor Pharmacology,Biomarkers","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:04","last_checked":"2026-07-04 07:00:41","bibtex":null,"source_record_id":"DOI:10.1016/s0924-9338(14)77609-6","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/s0924-9338(14)77609-6","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/s0924-9338(14)77609-6","source_url":"https://doi.org/10.1016/s0924-9338(14)77609-6","doi":"10.1016/s0924-9338(14)77609-6","pmid":"","publication_date":"2013-12-31","importer_version":"2.1.3","text_redistributed":false}},{"id":5302,"title":"EPA-1211 - Role of 5-HT2a and mglu2 as a gpcr heterocomplex in antipsychotic action","authors":"Javier González-Maeso","journal":"European Psychiatry","publication_date":"2013-12-31","publication_year":2013,"doi":"10.1016/s0924-9338(14)78457-3","pubmed_id":null,"openalex_id":"https://openalex.org/W1970799783","source_url":"https://doi.org/10.1016/s0924-9338(14)78457-3","substance_tags":"psilocybin","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:04","last_checked":"2026-07-04 07:00:41","bibtex":null,"source_record_id":"DOI:10.1016/s0924-9338(14)78457-3","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/s0924-9338(14)78457-3","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/s0924-9338(14)78457-3","source_url":"https://doi.org/10.1016/s0924-9338(14)78457-3","doi":"10.1016/s0924-9338(14)78457-3","pmid":"","publication_date":"2013-12-31","importer_version":"2.1.3","text_redistributed":false}},{"id":5268,"title":"5HT2a Receptors - a New Target for Depression?","authors":"D.J. Nutt","journal":"European Psychiatry","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1016/s0924-9338(15)30027-4","pubmed_id":null,"openalex_id":"https://openalex.org/W562065783","source_url":"https://doi.org/10.1016/s0924-9338(15)30027-4","substance_tags":"psilocybin","topic_tags":"Depression,Receptor Pharmacology,Default Mode Network","study_type":"Other","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:04","last_checked":"2026-08-09 08:25:53","bibtex":null,"source_record_id":"DOI:10.1016/s0924-9338(15)30027-4","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/s0924-9338(15)30027-4","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/s0924-9338(15)30027-4","source_url":"https://doi.org/10.1016/s0924-9338(15)30027-4","doi":"10.1016/s0924-9338(15)30027-4","pmid":"","publication_date":"2015-03-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5267,"title":"The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making","authors":"Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann, I. Dziobek, Philipp Stämpfli, F.X. Vollenweider","journal":"European Psychiatry","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1016/s0924-9338(15)30017-1","pubmed_id":null,"openalex_id":"https://openalex.org/W563138297","source_url":"https://doi.org/10.1016/s0924-9338(15)30017-1","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Chronic Pain,Brain Imaging,Receptor Pharmacology,Emotional Processing,Healthy Volunteers,Drug Interactions","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:04","last_checked":"2026-08-09 08:25:53","bibtex":null,"source_record_id":"DOI:10.1016/s0924-9338(15)30017-1","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/s0924-9338(15)30017-1","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/s0924-9338(15)30017-1","source_url":"https://doi.org/10.1016/s0924-9338(15)30017-1","doi":"10.1016/s0924-9338(15)30017-1","pmid":"","publication_date":"2015-03-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5248,"title":"The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)","authors":"Laura Orsolini, Alessandro Valchera, Duccio Papanti, R. Vecchiotti, Domenico De Berardis","journal":"European Psychiatry","publication_date":"2016-02-29","publication_year":2016,"doi":"10.1016/j.eurpsy.2016.01.1060","pubmed_id":null,"openalex_id":"https://openalex.org/W2376514477","source_url":"https://doi.org/10.1016/j.eurpsy.2016.01.1060","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology,Receptor Pharmacology,Review Article,Case Report,Safety,Toxicity","study_type":"Review Article","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:52:03","last_checked":"2026-07-04 07:00:40","bibtex":null,"source_record_id":"DOI:10.1016/j.eurpsy.2016.01.1060","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1016/j.eurpsy.2016.01.1060","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1016/j.eurpsy.2016.01.1060","source_url":"https://doi.org/10.1016/j.eurpsy.2016.01.1060","doi":"10.1016/j.eurpsy.2016.01.1060","pmid":"","publication_date":"2016-02-29","importer_version":"2.1.3","text_redistributed":false}},{"id":5113,"title":"Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?","authors":"Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos, Guilherme Borges","journal":"European Psychiatry","publication_date":"2021-04-01","publication_year":2021,"doi":"10.1192/j.eurpsy.2021.1114","pubmed_id":null,"openalex_id":"https://openalex.org/W4212954018","source_url":"https://doi.org/10.1192/j.eurpsy.2021.1114","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,OCD,Receptor Pharmacology,Aging,Clinical Trial,Systematic Review,Review Article,Case Report,Treatment-Resistant Depression","study_type":"Systematic Review","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:59","last_checked":"2026-08-09 08:25:46","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2021.1114","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2021.1114","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2021.1114","source_url":"https://doi.org/10.1192/j.eurpsy.2021.1114","doi":"10.1192/j.eurpsy.2021.1114","pmid":"","publication_date":"2021-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":5112,"title":"Effects of psilocybin-assisted therapy on treatment-resistant depression","authors":"A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira, Margarida Albuquerque, M. Costa, Paulo Santos, Nuno Moura, A. Moutinho","journal":"European Psychiatry","publication_date":"2021-04-01","publication_year":2021,"doi":"10.1192/j.eurpsy.2021.1836","pubmed_id":null,"openalex_id":"https://openalex.org/W3212256162","source_url":"https://doi.org/10.1192/j.eurpsy.2021.1836","substance_tags":"psilocybin","topic_tags":"Depression,Anxiety,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:59","last_checked":"2026-08-09 08:25:46","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2021.1836","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2021.1836","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2021.1836","source_url":"https://doi.org/10.1192/j.eurpsy.2021.1836","doi":"10.1192/j.eurpsy.2021.1836","pmid":"","publication_date":"2021-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4958,"title":"Association of Psilocybin Use in Adolescents with Major Depressive Episode","authors":"Kaushal Shah, C. Trivedi, D. Kamrai, M. Akbar, W. Tankersley","journal":"European Psychiatry","publication_date":"2022-06-01","publication_year":2022,"doi":"10.1192/j.eurpsy.2022.837","pubmed_id":null,"openalex_id":"https://openalex.org/W4294189301","source_url":"https://doi.org/10.1192/j.eurpsy.2022.837","substance_tags":"psilocybin","topic_tags":"Depression,Observational Study,Adolescents","study_type":"Observational Study","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:51:57","last_checked":"2026-08-09 08:25:41","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2022.837","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2022.837","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2022.837","source_url":"https://doi.org/10.1192/j.eurpsy.2022.837","doi":"10.1192/j.eurpsy.2022.837","pmid":"","publication_date":"2022-06-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4840,"title":"The Effects of Serotonergic Psychedelics on Neural Activity: A Meta-Analysis of Task-Based Functional Neuroimaging Studies","authors":"J. H. Shepherd, C.T.M. Baten, A. C. Klassen, G. Zamora, Sarah Saravia, Elizabeth Pritchard, Ziad A. Ali, S. K. Kahlon, Kyla Whitelock, F. A. Reyes, D. W. Hedges, J. Paul Hamilton, Matthew D. Sacchet, Chris H. Miller","journal":"European Psychiatry","publication_date":"2023-02-28","publication_year":2023,"doi":"10.1192/j.eurpsy.2023.1948","pubmed_id":null,"openalex_id":"https://openalex.org/W4385669097","source_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.1948","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Receptor Pharmacology,Aging,Meta-Analysis,Healthy Volunteers,Toxicity","study_type":"Meta-Analysis","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:46","last_checked":"2026-07-04 07:00:37","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2023.1948","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.1948","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2023.1948","source_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.1948","doi":"10.1192/j.eurpsy.2023.1948","pmid":"","publication_date":"2023-02-28","importer_version":"2.1.3","text_redistributed":false}},{"id":4658,"title":"Current situation regarding psychedelics and magic mushroom in Korea","authors":"J. S. Seo","journal":"European Psychiatry","publication_date":"2024-04-01","publication_year":2024,"doi":"10.1192/j.eurpsy.2024.1695","pubmed_id":null,"openalex_id":"https://openalex.org/W4401921810","source_url":"http://dx.doi.org/10.1192/j.eurpsy.2024.1695","substance_tags":"psilocybin,psilocin","topic_tags":"Depression,Anxiety,End-of-Life Distress,Clinical Trial,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:43","last_checked":"2026-08-09 08:25:30","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2024.1695","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"http://dx.doi.org/10.1192/j.eurpsy.2024.1695","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2024.1695","source_url":"http://dx.doi.org/10.1192/j.eurpsy.2024.1695","doi":"10.1192/j.eurpsy.2024.1695","pmid":"","publication_date":"2024-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4646,"title":"Microdosing psychedelics in the treatment of ADHD and comorbid disorders","authors":"Kim P. C. Kuypers","journal":"European Psychiatry","publication_date":"2024-04-01","publication_year":2024,"doi":"10.1192/j.eurpsy.2024.44","pubmed_id":null,"openalex_id":"https://openalex.org/W4401920710","source_url":"https://doi.org/10.1192/j.eurpsy.2024.44","substance_tags":"psilocybin","topic_tags":"Depression,Chronic Pain,Neuroplasticity,Default Mode Network,Microdosing,Personality Change,Emotional Processing,Clinical Trial,Observational Study","study_type":"Clinical Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:43","last_checked":"2026-08-09 08:25:30","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2024.44","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2024.44","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2024.44","source_url":"https://doi.org/10.1192/j.eurpsy.2024.44","doi":"10.1192/j.eurpsy.2024.44","pmid":"","publication_date":"2024-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4420,"title":"Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders","authors":"Ioana A. Cristea, G Tomei, Jazmín Freddi, A. Bonessio","journal":"European Psychiatry","publication_date":"2025-04-01","publication_year":2025,"doi":"10.1192/j.eurpsy.2025.393","pubmed_id":null,"openalex_id":"https://openalex.org/W4414208490","source_url":"https://doi.org/10.1192/j.eurpsy.2025.393","substance_tags":"psilocybin","topic_tags":"Clinical Trial,Randomized Controlled Trial,Review Article,Observational Study,Safety","study_type":"Randomized Controlled Trial","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:40","last_checked":"2026-08-09 08:25:22","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2025.393","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2025.393","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2025.393","source_url":"https://doi.org/10.1192/j.eurpsy.2025.393","doi":"10.1192/j.eurpsy.2025.393","pmid":"","publication_date":"2025-04-01","importer_version":"2.1.3","text_redistributed":false}},{"id":4410,"title":"Reporting of psychotherapeutic methods in psychedelic treatments: on the road to ethical, professional and regulatory oversight","authors":"A. Oliveira-Maia","journal":"European Psychiatry","publication_date":"2025-04-01","publication_year":2025,"doi":"10.1192/j.eurpsy.2025.64","pubmed_id":null,"openalex_id":"https://openalex.org/W4414181599","source_url":"https://doi.org/10.1192/j.eurpsy.2025.64","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Systematic Review,Review Article,Safety","study_type":"Systematic Review","source_name":"OpenAlex","publication_status":"published","date_added":"2026-07-04 06:34:40","last_checked":"2026-08-09 08:25:22","bibtex":null,"source_record_id":"DOI:10.1192/j.eurpsy.2025.64","abstract_available":true,"abstract_source":"OpenAlex","abstract_source_url":"https://doi.org/10.1192/j.eurpsy.2025.64","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"OpenAlex","source_record_id":"DOI:10.1192/j.eurpsy.2025.64","source_url":"https://doi.org/10.1192/j.eurpsy.2025.64","doi":"10.1192/j.eurpsy.2025.64","pmid":"","publication_date":"2025-04-01","importer_version":"2.1.3","text_redistributed":false}}],"total":15,"page":1,"per_page":20,"pages":1,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"European Psychiatry","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}